Takeda Pharmaceutical (4502) Stock Overview
Engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 5/6 |
4502 Community Fair Values
Create NarrativeSee what 22 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Pharmaceuticals & Biotech opportunity
ST
Fair Value from
US$21.5363.1% undervalued intrinsic discount
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.
Read full narrativeTakeda Pharmaceutical Company Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥5,162.00 |
| 52 Week High | JP¥6,033.00 |
| 52 Week Low | JP¥4,000.00 |
| Beta | 0.098 |
| 1 Month Change | -9.94% |
| 3 Month Change | -7.51% |
| 1 Year Change | 29.05% |
| 3 Year Change | 14.97% |
| 5 Year Change | 37.00% |
| Change since IPO | 282.37% |
Recent News & Updates
Narrative Update • Apr 29
4502: Late Stage Pipeline And Leadership Transition Will Underpin Bullish Outlook
Analysts have nudged their Takeda Pharmaceutical price target slightly higher to ¥6,036.87 from ¥6,003.53, reflecting updated assumptions around modestly adjusted revenue growth, a small change in expected profit margins, and a steady forward P/E outlook. What's in the News Takeda plans a leadership transition, with current CEO Christophe Weber expected to retire on June 24, 2026, subject to approval at the 150th Ordinary General Meeting of Shareholders.Narrative Update • Apr 12
4502: Fair Outlook Will Depend On Late Stage Pipeline And Legal Outcomes
Analysts have adjusted their price target on Takeda Pharmaceutical from about ¥5,697 to roughly ¥6,004, reflecting updated assumptions around revenue growth, profit margins, and future P/E expectations. What's in the News Takeda plans a leadership transition, with current CEO Christophe Weber set to retire at the 150th Ordinary General Meeting of Shareholders on June 24, 2026.
New Narrative • Apr 02
Pipeline Progress And New Launches Will Secure Durable Long Term Earnings Power
Catalysts About Takeda Pharmaceutical Takeda Pharmaceutical is a global R&D driven biopharmaceutical company focused on specialty medicines across areas such as gastroenterology, rare diseases, plasma derived therapies, oncology, neuroscience and vaccines. What are the underlying business or industry changes driving this perspective?Narrative Update • Mar 29
4502: Fair Outlook Will Depend On Pipeline Progress And Ongoing Legal Proceedings
Analysts now set their fair value estimate for Takeda Pharmaceutical at about ¥5,697, up from roughly ¥5,590. This reflects updated assumptions around slightly higher revenue growth, a similar discount rate, a modestly adjusted profit margin and a future P/E of about 32.5x.Recent updates
Narrative Update • Apr 29
4502: Late Stage Pipeline And Leadership Transition Will Underpin Bullish Outlook
Analysts have nudged their Takeda Pharmaceutical price target slightly higher to ¥6,036.87 from ¥6,003.53, reflecting updated assumptions around modestly adjusted revenue growth, a small change in expected profit margins, and a steady forward P/E outlook. What's in the News Takeda plans a leadership transition, with current CEO Christophe Weber expected to retire on June 24, 2026, subject to approval at the 150th Ordinary General Meeting of Shareholders.Narrative Update • Apr 12
4502: Fair Outlook Will Depend On Late Stage Pipeline And Legal Outcomes
Analysts have adjusted their price target on Takeda Pharmaceutical from about ¥5,697 to roughly ¥6,004, reflecting updated assumptions around revenue growth, profit margins, and future P/E expectations. What's in the News Takeda plans a leadership transition, with current CEO Christophe Weber set to retire at the 150th Ordinary General Meeting of Shareholders on June 24, 2026.New Narrative • Apr 02
Pipeline Progress And New Launches Will Secure Durable Long Term Earnings Power
Catalysts About Takeda Pharmaceutical Takeda Pharmaceutical is a global R&D driven biopharmaceutical company focused on specialty medicines across areas such as gastroenterology, rare diseases, plasma derived therapies, oncology, neuroscience and vaccines. What are the underlying business or industry changes driving this perspective?Narrative Update • Mar 29
4502: Fair Outlook Will Depend On Pipeline Progress And Ongoing Legal Proceedings
Analysts now set their fair value estimate for Takeda Pharmaceutical at about ¥5,697, up from roughly ¥5,590. This reflects updated assumptions around slightly higher revenue growth, a similar discount rate, a modestly adjusted profit margin and a future P/E of about 32.5x.Narrative Update • Mar 13
4502: Fair Outlook Will Rely On Pipeline Progress And Legal Risk Management
Analysts have adjusted their price target on Takeda Pharmaceutical to ¥5,590 from ¥5,463, reflecting updated views on fair value, profit margin assumptions, and expected future P/E ratios while keeping the discount rate broadly unchanged. What's in the News A U.S. national third party payor class has been certified in a class action lawsuit related to Actos and associated products, alleging violations of the Racketeer Influenced and Corrupt Organizations Act, with Takeda and Eli Lilly as defendants and an opt out deadline for class members set for April 6, 2026 (Lawsuits & Legal Issues).
New Narrative • Mar 11
Late Stage Pipeline And Pricing Pressures Will Constrain Future Earnings Potential
Catalysts About Takeda Pharmaceutical Takeda Pharmaceutical is a global R&D driven biopharmaceutical company focused on specialty care, including gastroenterology, rare diseases, plasma derived therapies, oncology, neuroscience and vaccines. What are the underlying business or industry changes driving this perspective?Narrative Update • Feb 26
4502: Fair Outlook Will Depend On Pipeline Progress And Steady Dividend Policy
Narrative Update: Takeda Pharmaceutical Price Target Shift The analyst price target for Takeda Pharmaceutical has moved by ¥200 to ¥5,463, with analysts citing updated assumptions around modestly higher revenue growth, a slightly lower profit margin, and a revised future P/E of 31.18x as key drivers of the new view. What’s in the News Takeda reported positive Phase 3 KEPLER trial data for ENTYVIO (vedolizumab) in patients ages 2 and older with moderately to severely active ulcerative colitis, and plans marketing applications in the US, EU and other markets for pediatric use of intravenous ENTYVIO.Narrative Update • Feb 11
4502: Fair Outlook Will Rely On Drug Approvals And Sustained Dividends
Analysts have nudged their price target on Takeda Pharmaceutical higher from about ¥5,196 to roughly ¥5,263, reflecting updated views on discount rate assumptions, revenue growth, profit margins, and future P/E expectations. What's in the News The U.S. FDA accepted Takeda's New Drug Application and granted Priority Review for orexin agonist TAK-861 for narcolepsy type 1, with a PDUFA goal date set in the third quarter of this calendar year (Key Developments).Analysis Article • Feb 08
Investors Can Find Comfort In Takeda Pharmaceutical's (TSE:4502) Earnings Quality
The market was pleased with the recent earnings report from Takeda Pharmaceutical Company Limited ( TSE:4502 ), despite...Analysis Article • Feb 03
Takeda Pharmaceutical (TSE:4502) Is Due To Pay A Dividend Of ¥100.00
Takeda Pharmaceutical Company Limited ( TSE:4502 ) has announced that it will pay a dividend of ¥100.00 per share on...Analysis Article • Jan 31
Takeda Pharmaceutical Company Limited Just Recorded A 26% EPS Beat: Here's What Analysts Are Forecasting Next
It's been a good week for Takeda Pharmaceutical Company Limited ( TSE:4502 ) shareholders, because the company has just...Narrative Update • Jan 27
4502: Fair Outlook Will Depend On Pipeline Progress And Sustained Dividends
Analysts have adjusted their price target for Takeda Pharmaceutical to ¥5,196.40 from ¥4,946.14, citing updated assumptions for revenue growth, profit margin, and future P/E that slightly raise their assessed fair value. What's in the News Takeda declared a dividend of ¥100.00 per share for the second quarter of the fiscal year ending March 31, 2026, compared with ¥98.00 per share paid a year earlier, with payment scheduled to start on December 1, 2025 (company announcement).Analysis Article • Jan 19
Takeda Pharmaceutical (TSE:4502) Has Announced A Dividend Of ¥100.00
The board of Takeda Pharmaceutical Company Limited ( TSE:4502 ) has announced that it will pay a dividend of ¥100.00...Narrative Update • Jan 08
4502: Stable Outlook Will Rely On Late Stage Pipeline And Dividends
Analysts kept their price target for Takeda Pharmaceutical steady at ¥4,946, reflecting largely unchanged assumptions around modest revenue growth, stable profit margins, and a future P/E of about 27x. What's in the News Takeda and Protagonist Therapeutics submitted a New Drug Application to the U.S. FDA for rusfertide for adults with polycythemia vera, following Phase 3 VERIFY and Phase 2 REVIVE data and multiple FDA designations including Breakthrough Therapy and Orphan Drug (Key Developments).Analysis Article • Jan 05
Takeda Pharmaceutical (TSE:4502) Will Pay A Dividend Of ¥100.00
Takeda Pharmaceutical Company Limited ( TSE:4502 ) will pay a dividend of ¥100.00 on the 26th of June. This takes the...Narrative Update • Dec 21
4502: Future Pipeline And Focused R D Shift Will Shape Balanced Outlook
Analysts have modestly raised their price target on Takeda Pharmaceutical to 4,946 yen, reflecting steady expectations for revenue growth, profit margins, and future valuation multiples despite only marginal adjustments to their models. What's in the News Positive Phase 3 results for zasocitinib (TAK-279) in moderate to severe plaque psoriasis, with superiority to placebo and apremilast across primary and 44 ranked secondary endpoints, support the potential of a once daily oral TYK2 inhibitor in dermatology.Analysis Article • Dec 17
Takeda Pharmaceutical (TSE:4502) Will Pay A Dividend Of ¥100.00
The board of Takeda Pharmaceutical Company Limited ( TSE:4502 ) has announced that it will pay a dividend on the 26th...Narrative Update • Dec 07
4502: Future Specialty Pipeline And Leadership Change Will Drive Upside Outlook
Analysts have nudged their fair value estimate for Takeda Pharmaceutical modestly higher to approximately ¥4,946 from about ¥4,906, reflecting slightly stronger long term revenue growth expectations and a marginally higher future earnings multiple, despite a small compression in projected profit margins. What's in the News Revised guidance for fiscal year 2025 points to softer top line and a sharper drop in reported operating profit, driven by weaker ENTYVIO and VYVANSE sales, unfavorable product mix and higher expected impairments, partly offset by R and D cost savings (company guidance).Analysis Article • Dec 03
Takeda Pharmaceutical (TSE:4502) Has Announced A Dividend Of ¥100.00
Takeda Pharmaceutical Company Limited ( TSE:4502 ) has announced that it will pay a dividend of ¥100.00 per share on...Narrative Update • Nov 23
4502: Future Pipeline Progress And Leadership Transition Will Shape Steady Outlook
Narrative Update on Takeda Pharmaceutical: Analyst Price Target Revision Analysts have maintained Takeda Pharmaceutical's fair value estimate at ¥4,906.40. This reflects minimal adjustments to revenue growth and profit margin forecasts while keeping the overall outlook stable.Narrative Update • Nov 06
4502: Sustained Clinical Momentum And Management Transition Will Drive Future Upside
Narrative Update: Takeda Pharmaceutical Analyst Price Target Revision Analysts have slightly reduced their price target for Takeda Pharmaceutical, lowering it from ¥4,950 to ¥4,906. This change reflects modest adjustments in forecasted revenue growth and profit margin expectations.Analysis Article • Nov 01
Takeda Pharmaceutical Company Limited Just Missed Earnings - But Analysts Have Updated Their Models
As you might know, Takeda Pharmaceutical Company Limited ( TSE:4502 ) last week released its latest interim, and things...Narrative Update • Oct 23
Takeda Analyst Price Target Eases as Company Refocuses Strategy Fuelled by Recent Developments
Takeda Pharmaceutical's analyst price target has been revised downward from ¥5,002.88 to ¥4,949.73, as analysts' slightly reduced revenue growth projections are now balanced by improved profit margin expectations. What's in the News Takeda and Innovent Biologics entered a strategic global partnership to accelerate development of next-generation cancer therapies, including several investigational immuno-oncology and antibody-drug conjugate medicines.Narrative Update • Oct 09
Pipeline Advances In Rare Diseases Will Revitalize Future Healthcare Markets
Analysts have modestly lowered their price target for Takeda Pharmaceutical, reducing the fair value estimate from ¥5,056.07 to ¥5,002.88. They cite slightly softer outlooks for revenue growth and profit margins as the reason for this adjustment.Analysis Article • Sep 17
Takeda Pharmaceutical (TSE:4502) Is Increasing Its Dividend To ¥100.00
Takeda Pharmaceutical Company Limited ( TSE:4502 ) will increase its dividend from last year's comparable payment on...Analysis Article • Sep 03
Takeda Pharmaceutical (TSE:4502) Is Increasing Its Dividend To ¥100.00
Takeda Pharmaceutical Company Limited's ( TSE:4502 ) dividend will be increasing from last year's payment of the same...Narrative Update • Aug 31
Pipeline Advances In Rare Diseases Will Revitalize Future Healthcare Markets
Takeda Pharmaceutical's consensus price target saw a modest increase to ¥5,056, primarily reflecting a slight upward revision in forecasted annual revenue growth. What's in the News Takeda released positive Phase 3 data for oveporexton (TAK-861), an investigational orexin receptor 2 agonist, in narcolepsy type 1; both studies met all endpoints and showed significant improvements in sleepiness and cataplexy frequency versus placebo.Analysis Article • Aug 08
Takeda Pharmaceutical's (TSE:4502) Soft Earnings Are Actually Better Than They Appear
TSE:4502 1 Year Share Price vs Fair Value Explore Takeda Pharmaceutical's Fair Values from the Community and select...Analysis Article • Aug 07
Takeda Pharmaceutical's (TSE:4502) Upcoming Dividend Will Be Larger Than Last Year's
Takeda Pharmaceutical Company Limited ( TSE:4502 ) has announced that it will be increasing its dividend from last...Analysis Article • Aug 02
Takeda Pharmaceutical Company Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Takeda Pharmaceutical Company Limited ( TSE:4502 ) shareholders are probably feeling a little disappointed, since its...Analysis Article • Jul 24
Takeda Pharmaceutical (TSE:4502) Is Increasing Its Dividend To ¥100.00
The board of Takeda Pharmaceutical Company Limited ( TSE:4502 ) has announced that it will be paying its dividend of...Analysis Article • Jul 10
Takeda Pharmaceutical (TSE:4502) Will Pay A Larger Dividend Than Last Year At ¥100.00
Takeda Pharmaceutical Company Limited's ( TSE:4502 ) dividend will be increasing from last year's payment of the same...Analysis Article • Jun 28
Takeda Pharmaceutical Company Limited Just Missed Earnings - But Analysts Have Updated Their Models
Takeda Pharmaceutical Company Limited ( TSE:4502 ) last week reported its latest annual results, which makes it a good...Shareholder Returns
| 4502 | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | -1.5% | -1.2% | 2.9% |
| 1Y | 29.0% | 12.0% | 39.4% |
Return vs Industry: 4502 exceeded the JP Pharmaceuticals industry which returned 12% over the past year.
Return vs Market: 4502 underperformed the JP Market which returned 39.4% over the past year.
Price Volatility
| 4502 volatility | |
|---|---|
| 4502 Average Weekly Movement | 3.4% |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in JP Market | 9.7% |
| 10% least volatile stocks in JP Market | 2.4% |
Stable Share Price: 4502 has not had significant price volatility in the past 3 months compared to the JP market.
Volatility Over Time: 4502's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1781 | 47,455 | Christophe P. Weber | www.takeda.com |
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba Fiber, Recombinate, Hemofil, Immunate, Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands.
Takeda Pharmaceutical Company Limited Fundamentals Summary
| 4502 fundamental statistics | |
|---|---|
| Market cap | JP¥8.16t |
| Earnings (TTM) | JP¥112.93b |
| Revenue (TTM) | JP¥4.46t |
72.2x
P/E Ratio1.8x
P/S RatioIs 4502 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4502 income statement (TTM) | |
|---|---|
| Revenue | JP¥4.46t |
| Cost of Revenue | JP¥1.54t |
| Gross Profit | JP¥2.93t |
| Other Expenses | JP¥2.81t |
| Earnings | JP¥112.93b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
May 13, 2026
| Earnings per share (EPS) | 71.48 |
| Gross Margin | 65.53% |
| Net Profit Margin | 2.53% |
| Debt/Equity Ratio | 63.5% |
How did 4502 perform over the long term?
See historical performance and comparisonDividends
3.9%
Current Dividend Yield276%
Payout RatioDoes 4502 pay a reliable dividends?
See 4502 dividend history and benchmarks| Takeda Pharmaceutical dividend dates | |
|---|---|
| Ex Dividend Date | Mar 30 2026 |
| Dividend Pay Date | Jun 26 2026 |
| Days until Ex dividend | 43 days |
| Days until Dividend pay date | 45 days |
Does 4502 pay a reliable dividends?
See 4502 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/11 16:55 |
| End of Day Share Price | 2026/05/11 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Takeda Pharmaceutical Company Limited is covered by 29 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Atsushi Seki | Barclays |
| Miki Sogi | Bernstein |
| Koichi Mamegano | BofA Global Research |